Biomarker panel to differentiate stroke from stroke mimic
Biomarker panel to differentiate stroke from stroke mimic
批准号:
7405215
负责人:
Albert K Man
金额:
$25.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2010-02-28
关键词:
Accident and Emergency departmentAdmission activityAffectAgeAlgorithmsAlteplaseBiological AssayBiological MarkersBlood TestsBlood specimenBrain InjuriesBrain hemorrhageCardiovascular DiseasesCause of DeathCessation of lifeCharacteristicsClinicalClinical DataCoagulation ProcessConditionContractsDataData AnalysesData SetDevelopmentDiagnosisDiagnosticEconomic BurdenEffectivenessEnzyme-Linked Immunosorbent AssayFacilities and Administrative CostsGoalsHospitalsHourImageImage AnalysisImmunoassayIschemic StrokeLesionMachine LearningMagnetic Resonance ImagingManufacturer NameMeasuresMedicalMethodologyModelingMolecularOutcomePatientsPerformancePharmaceutical PreparationsPhasePlasmaPrognostic MarkerProteinsRecording of previous eventsReproducibilitySafetySamplingScienceSensitivity and SpecificitySeveritiesSocietiesSpeedStrokeSymptomsTechnologyTestingTherapeutic InterventionTimeUnited StatesValidationX-Ray Computed Tomographybaseclinical Diagnosisclinically significantoncologypredictive modelingpreventrapid techniquesocialstatisticsvalidation studies
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In the United States (US), stroke affects more than 700,000 people annually in the U.S. and is the third leading cause of death. Stroke patients may present to the emergency room with a wide variety of symptoms that can be caused by other conditions not related to stroke, collectively called stroke mimic. Even at the most advanced stroke centers, the diagnosis of ischemic stroke is made by clinical examination after ruling out hemorrhagic lesions by imaging. These imaging tests can be used to diagnose hemorrhagic stroke but is relatively ineffective in detecting most ischemic stroke. A reliable and rapid method to distinguish stroke and stroke mimic is a necessary aid to current examination and imaging-based stroke diagnosis and will become more crucial with the implementation of new therapies for the time-critical treatment of ischemic stroke. In contrast to cardiovascular disease and oncology, no approved immunoassay or molecular test is available to aid diagnosis. Analysis of a previous dataset demonstrated that our advanced GeneRx algorithm technologies were able to develop an accurate diagnostic model where other multi-marker panels failed. In this phase I proposal we will perform a validation study, collecting blood samples from 200 admitted with stroke-like symptoms and diagnosed as stroke or stroke mimic. We will measure stroke biomarker protein levels markers present in the top combinations and algorithms from our previous study, and utilize our proprietary GeneRx technology to develop a multiple marker predictive model for accurate differentiation of stroke from stroke mimic. Project Narrative: Currently no blood test is available to help accurately diagnose stroke patients. This study develops a diagnostic to help differentiate stroke patients from the many non-stroke patients that arrive at the ER with stroke-like symptoms. Successful development of this diagnostic will increase the effectiveness and speed of stroke treatment to increase a patient's chances of improvement and safety of treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Stroke Point of Care Immunoassay for Cellular Fibronectin
-
批准号:7941816
-
项目类别:
-
资助金额:$60.2万
-
财政年份:2007
-
负责人:Albert K Man
-
依托单位:
c-FN as a predictor of hemorrhagic transformation in t-PA treated stroke patients
-
批准号:7220477
-
项目类别:
-
资助金额:$20.62万
-
财政年份:2007
-
负责人:Albert K Man
-
依托单位: